Oxford BioDynamics Plc (LON:OBD – Get Free Report)’s share price traded up 5.3% during trading on Monday . The stock traded as high as GBX 0.18 and last traded at GBX 0.18. Approximately 3,021,327 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 14,009,450 shares. The stock had previously closed at GBX 0.17.
Oxford BioDynamics Stock Performance
The company has a current ratio of 0.88, a quick ratio of 2.80 and a debt-to-equity ratio of 457.97. The firm’s fifty day moving average price is GBX 0.19 and its two-hundred day moving average price is GBX 0.23. The stock has a market capitalization of £6.91 million, a PE ratio of -0.20 and a beta of 0.42.
About Oxford BioDynamics
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
Read More
- Five stocks we like better than Oxford BioDynamics
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
